We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-24.91%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.09B
AUM Growth
-$580M
Cap. Flow
-$124M
Cap. Flow %
-11.41%
Top 10 Hldgs %
62.53%
Holding
60
New
14
Increased
22
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
QTTB icon
Q32 Bio
QTTB
+$25.2M
2
ADVM
Adverum Biotechnologies
ADVM
+$24.7M
3
SAGE
Sage Therapeutics
SAGE
+$19M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$17.7M
5
ASMB icon
Assembly Biosciences
ASMB
+$16.6M

Top Sells

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$60.4M
2
PTCT icon
PTC Therapeutics
PTCT
+$48.7M
3
CORI
Corium International, Inc.
CORI
+$34.3M
4
ARWR icon
Arrowhead Research
ARWR
+$31.3M
5
ILMN icon
Illumina
ILMN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$236M 21.64%
16,037,486
+1,067,742
+7% +$17.7M
ARWR icon
2
Arrowhead Research
ARWR
$12.1B
$66M 6.06%
5,316,156
-2,288,069
-30% -$31.3M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$66M 6.05%
1,922,346
-1,353,245
-41% -$48.7M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$63.1M 5.79%
5,907,088
+445,964
+8% +$5.87M
BMY icon
5
Bristol-Myers Squibb
BMY
$127B
$49.4M 4.53%
950,780
+3,819
+0.4% +$205K
RGNX icon
6
Regenxbio
RGNX
$623M
$44.1M 4.04%
1,050,245
-408,883
-28% -$24M
LIVN icon
7
LivaNova
LIVN
$4.3B
$40.5M 3.72%
443,036
– –
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.66B
$39.9M 3.66%
365,911
+51,841
+17% +$6.48M
VCEL icon
9
Vericel Corp
VCEL
$2.3B
$39.8M 3.65%
2,289,134
+71,218
+3% +$1.07M
MASI
10
DELISTED
Masimo
MASI
$36.7M 3.37%
342,221
+31,760
+10% +$3.54M
QTTB icon
11
Q32 Bio
QTTB
$450M
$36.5M 3.35%
90,750
+66,588
+276% +$25.2M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$36.3B
$32M 2.94%
439,498
+50,426
+13% +$3.88M
AGEN
13
Agenus
AGEN
$249M
$24.1M 2.21%
516,384
+15,822
+3% +$660K
ESTA icon
14
Establishment Labs
ESTA
$2.72B
$22.7M 2.09%
848,058
+72,249
+9% +$1.77M
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
$21.9M 2.01%
13,749,383
+153,679
+1% +$434K
ADVM
16
DELISTED
Adverum Biotechnologies
ADVM
$19.7M 1.81%
625,684
+607,202
+3,285% +$24.7M
SIBN icon
17
SI-BONE Inc
SIBN
$737M
$16.8M 1.54%
+804,327
New +$15.2M
ABUS icon
18
Arbutus Biopharma
ABUS
$865M
$16.6M 1.52%
4,335,746
+250,842
+6% +$1.24M
AXNX
19
DELISTED
Axonics, Inc. Common Stock
AXNX
$16.6M 1.52%
+1,095,396
New +$16.3M
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$15.9M 1.46%
+165,990
New +$19M
ASMB icon
21
Assembly Biosciences
ASMB
$506M
$15.5M 1.43%
+57,220
New +$16.6M
APYX icon
22
Apyx Medical
APYX
$165M
$15.5M 1.42%
2,391,898
+156,351
+7% +$947K
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.4M 1.32%
294,898
+20,981
+8% +$1.15M
PRNB
24
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$14.2M 1.3%
555,948
-88,500
-14% -$2.28M
CTMX icon
25
CytomX Therapeutics
CTMX
$705M
$13.7M 1.26%
+908,586
New +$13.5M
1
2 3

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q4 2018 Portfolio in Review

As of Q4 2018, RTW Investments held 60 positions worth $1.09B, down 35% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

RTW Investments withdrew a net $124M in Q4 2018, closing 12 positions and reducing 10 holdings. Its most notable exit was Corium International, Inc., an estimated $34.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

Against the trend, RTW Investments opened a new position in Sage Therapeutics worth $15.9M.

  • RTW Investments's largest Q4 2018 buy was Sage Therapeutics: 165,990 shares worth $15.9M.
  • RTW Investments added most to Q32 Bio in Q4 2018, an estimated $25.2M increase.
  • RTW Investments's biggest Q4 2018 reduction was ProQR Therapeutics, cutting an estimated $60.4M.
  • RTW Investments fully exited Corium International, Inc. in Q4 2018, selling an estimated $34.3M.
  • RTW Investments's ten largest holdings make up 63% of its $1.09B portfolio in Q4 2018.
  • RTW Investments opened 14 new positions and closed 12 in Q4 2018.
  • RTW Investments's portfolio value fell 35% quarter-over-quarter to $1.09B.

Based on RTW Investments's 13F filing for Q4 2018, filed 14 Feb 2019.